Literature DB >> 26822808

Prevalence of probiotic use among inpatients: A descriptive study of 145 U.S. hospitals.

Sarah H Yi1, John A Jernigan2, L Clifford McDonald2.   

Abstract

BACKGROUND: To inform clinical guidance, public health efforts, and research directions, probiotic use in U.S. health care needs to be better understood. This work aimed to assess the prevalence of inpatient probiotic use in a sample of U.S. hospitals.
METHODS: Probiotic use among patients discharged in 2012 was estimated using the MarketScan Hospital Drug Database. In addition, the annual trend in probiotic use (2006-2012) was assessed among a subset of hospitals.
RESULTS: Among 145 hospitals with 1,976,167 discharges in 2012, probiotics were used in 51,723 (2.6%) of hospitalizations occurring in 139 (96%) hospitals. Patients receiving probiotics were 9 times more likely to receive antimicrobials (P < .0001) and 21 times more likely to have a Clostridium difficile infection diagnosis (P < .0001). The most common probiotic formulations were Saccharomyces boulardii (32% of patients receiving probiotics), Lactobacillus acidophilus and Lactobacillus bulgaricus (30%), L acidophilus (28%), and Lactobacillus rhamnosus (11%). Probiotic use increased from 1.0% of 1,090,373 discharges in 2006 to 2.9% of 1,006,051 discharges in 2012 (P < .0001).
CONCLUSIONS: In this sample of U.S. hospitals, a sizable and growing number of inpatients received probiotics as part of their care despite inadequate evidence to support their use in this population. Additional research is needed to guide probiotic use in the hospital setting. Published by Elsevier Inc.

Entities:  

Keywords:  Bifidobacterium; Dietary supplement; Lactobacillus; Probiotic; Saccharomyces; hospital; microbial; prevalence

Mesh:

Year:  2016        PMID: 26822808     DOI: 10.1016/j.ajic.2015.12.001

Source DB:  PubMed          Journal:  Am J Infect Control        ISSN: 0196-6553            Impact factor:   2.918


  13 in total

1.  Risk of Subsequent Sepsis Within 90 Days After a Hospital Stay by Type of Antibiotic Exposure.

Authors:  James Baggs; John A Jernigan; Alison Laufer Halpin; Lauren Epstein; Kelly M Hatfield; L Clifford McDonald
Journal:  Clin Infect Dis       Date:  2018-03-19       Impact factor: 9.079

2.  Duration of Antibiotic Use Among Adults With Uncomplicated Community-Acquired Pneumonia Requiring Hospitalization in the United States.

Authors:  Sarah H Yi; Kelly M Hatfield; James Baggs; Lauri A Hicks; Arjun Srinivasan; Sujan Reddy; John A Jernigan
Journal:  Clin Infect Dis       Date:  2018-04-17       Impact factor: 9.079

Review 3.  Probiotics and gastrointestinal conditions: An overview of evidence from the Cochrane Collaboration.

Authors:  Elizabeth A Parker; Tina Roy; Christopher R D'Adamo; L Susan Wieland
Journal:  Nutrition       Date:  2017-07-06       Impact factor: 4.008

4.  Bifidobacterium Bacteremia: Clinical Characteristics and a Genomic Approach To Assess Pathogenicity.

Authors:  Eirin Esaiassen; Erik Hjerde; Jorunn Pauline Cavanagh; Gunnar Skov Simonsen; Claus Klingenberg
Journal:  J Clin Microbiol       Date:  2017-05-10       Impact factor: 5.948

5.  Effect of Probiotics on Incident Ventilator-Associated Pneumonia in Critically Ill Patients: A Randomized Clinical Trial.

Authors:  Jennie Johnstone; Maureen Meade; François Lauzier; John Marshall; Erick Duan; Joanna Dionne; Yaseen M Arabi; Diane Heels-Ansdell; Lehana Thabane; Daphnee Lamarche; Michael Surette; Nicole Zytaruk; Sangeeta Mehta; Peter Dodek; Lauralyn McIntyre; Shane English; Bram Rochwerg; Tim Karachi; William Henderson; Gordon Wood; Daniel Ovakim; Margaret Herridge; John Granton; M Elizabeth Wilcox; Alberto Goffi; Henry T Stelfox; Daniel Niven; John Muscedere; François Lamontagne; Frédérick D'Aragon; Charles St-Arnaud; Ian Ball; Dave Nagpal; Martin Girard; Pierre Aslanian; Emmanuel Charbonney; David Williamson; Wendy Sligl; Jan Friedrich; Neill K Adhikari; François Marquis; Patrick Archambault; Kosar Khwaja; Arnold Kristof; James Kutsogiannis; Ryan Zarychanski; Bojan Paunovic; Brenda Reeve; François Lellouche; Paul Hosek; Jennifer Tsang; Alexandra Binnie; Sébastien Trop; Osama Loubani; Richard Hall; Robert Cirone; Steve Reynolds; Paul Lysecki; Eyal Golan; Rodrigo Cartin-Ceba; Robert Taylor; Deborah Cook
Journal:  JAMA       Date:  2021-09-21       Impact factor: 56.272

6.  Challenges in Obtaining and Assessing Salivary Cortisol and α-Amylase in an Over 60 Population Undergoing Psychotherapeutic Treatment for Complicated Grief: Lessons Learned.

Authors:  Jesse M Bell; Tina M Mason; Harleah G Buck; Cindy S Tofthagen; Allyson R Duffy; Maureen W Groër; James P McHale; Kevin E Kip
Journal:  Clin Nurs Res       Date:  2020-11-20       Impact factor: 2.075

7.  Saccharomyces cerevisiae Laryngitis and Oral Lesions in a Patient with Laryngeal Carcinoma.

Authors:  Jumanah N Algazaq; Kevan Akrami; Fernando Martinez; Allen McCutchan; Ajay R Bharti
Journal:  Case Rep Infect Dis       Date:  2017-11-26

8.  Choosing an appropriate probiotic product for your patient: An evidence-based practical guide.

Authors:  Jason C Sniffen; Lynne V McFarland; Charlesnika T Evans; Ellie J C Goldstein
Journal:  PLoS One       Date:  2018-12-26       Impact factor: 3.240

Review 9.  Probiotics in Autoimmune and Inflammatory Disorders.

Authors:  Yuying Liu; Jane J Alookaran; J Marc Rhoads
Journal:  Nutrients       Date:  2018-10-18       Impact factor: 5.717

Review 10.  Clostridium species as probiotics: potentials and challenges.

Authors:  Pingting Guo; Ke Zhang; Xi Ma; Pingli He
Journal:  J Anim Sci Biotechnol       Date:  2020-02-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.